Omeza Holdings
Sarasota, US · Founded 2022 · Delaware corporation · 19 employees on LinkedIn · 3 known investors
Omeza is an ocean biotechnology company developing marine-based regenerative wound-care products, including its FDA-cleared OCM wound matrix made from cold-water fish peptides, omega fatty acids, and plant-derived lipids, to treat chronic, hard-to-heal wounds such as diabetic foot ulcers and venous leg ulcers in adults. The commercial-stage company serves the U.S. advanced wound care market and markets its products to clinical care sites.
Founders & leadership
CF
Cynthia FlowersExecutive
RG
Ronald GelbmanNamed on SEC filing
TG
Thomas GardnerNamed on SEC filing
JM
Joel MorganrothNamed on SEC filing
RE
Robert EssnerNamed on SEC filing
Board
AL
AG LafleyBoard director
RH
Richard HagueBoard director
FM
Frank MartuciBoard director
Investors · 3
Also in the syndicate · 2
AstanorleadBlukap Ventureslead
Funding
SEC filings, press & company announcements$22.3M disclosed across 5 rounds · 2022–2026
- $8.5MSeries aApr 2026 · 2 sources
Astanor (lead), Blukap Ventures (lead), Catalyst Investments
Source ↗
▶$906.3KraisedJan 2025 · 14 investors · Other Health CareRule 506(c)
▶$906.3KraisedJan 2025 · 14 investors · Other Health Care
Rule 506(c)Officers, directors & promoters on the filing
- AG LafleyDirector
- Cynthia FlowersExecutive Officer, Director
- Richard HagueDirector
- Frank MartuciDirector
- Offering amount
- $2.4M
- Amount sold
- $906.3K
- Minimum investment
- $12.5K
- First sale
- Dec 2024
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06c
▶$1.6MraisedSep 2023 · 12 investors · Other Health CareRule 506(b)
▶$1.6MraisedSep 2023 · 12 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Joel MorganrothDirector
- Robert EssnerDirector
- AG LafleyDirector
- Cynthia FlowersExecutive Officer, Director
- Offering amount
- $1.6M
- Amount sold
- $1.6M
- Minimum investment
- $50K
- First sale
- Nov 2022
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
▶$6.5MraisedSep 2023 · 39 investors · Other Health CareRule 506(b)
▶$6.5MraisedSep 2023 · 39 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Robert EssnerDirector
- Cynthia FlowersExecutive Officer, Director
- AG LafleyDirector
- Joel MorganrothDirector
- Offering amount
- $10M
- Amount sold
- $6.5M
- Minimum investment
- $25K
- First sale
- Jun 2023
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
▶$4.8MraisedMar 2022 · 27 investors · Other Health CareRule 506(b)
▶$4.8MraisedMar 2022 · 27 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Ronald GelbmanDirector
- Thomas GardnerExecutive Officer, Director
- Joel MorganrothDirector
- AG LafleyDirector
- Robert EssnerDirector
- Offering amount
- $5M
- Amount sold
- $4.8M
- Minimum investment
- $50K
- First sale
- Feb 2022
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlap
Practo4 shared keywordsPracto is a healthcare platform offering online video consultations with verified doctors across specialties and appointment booking for in-clinic visits. It serves patients in India, connecting them with doctors across areas such as dentistry, gynecology, pediatrics, and general medicine.
1Mg4 shared keywordsTata 1mg is India's leading online pharmacy and healthcare platform that offers medicines, lab tests, doctor consultations, and cancer care services. The company operates a digital marketplace serving Indian consumers seeking pharmaceuticals, diagnostic testing, and medical advice.
SoundCloud3 shared keywordsAudio distribution and music-sharing platform for artists and creators.
PharmEasy3 shared keywordsPharmEasy is a consumer healthcare platform offering on-demand home delivery of prescription and over-the-counter pharmaceuticals, diagnostic tests, and teleconsultation services in India.
Companies competing with Omeza Holdings for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Omeza Holdings do?
- Omeza is an ocean biotechnology company developing marine-based regenerative wound-care products, including its FDA-cleared OCM wound matrix made from cold-water fish peptides, omega fatty acids, and plant-derived lipids, to treat chronic, hard-to-heal wounds such as diabetic foot ulcers and venous leg ulcers in adults. The commercial-stage company serves the U.S. advanced wound care market and markets its products to clinical care sites.
- Who are Omeza Holdings's investors?
- Omeza Holdings's investors include Catalyst Investments.
- How much funding has Omeza Holdings raised?
- Omeza Holdings has disclosed $22.3M raised across 5 rounds.
- Where is Omeza Holdings headquartered?
- Omeza Holdings is headquartered in Sarasota, US.